Bita Sehat, PhD, MBA, is a Partner at Trill Impact advising on life science investments within Ventures. She writes on capital allocation, health care infrastructure, and the system dynamics that determine whether scientific progress translates into clinical impact.
As ATMP manufacturing capability matures, the limiting constraint has shifted from development to delivery. An analysis of Sweden's uniquely visible ecosystem identifies structural barriers that cannot be resolved through component-level optimization alone.
